By vgreene, 7 April, 2020 Ruxolitinib Managed Access Program (MAP) for Patients Diagnosed With Severe/Very Severe COVID-19 Illness, NCT04337359
By vgreene, 7 April, 2020 Proposed mechanism: reduces inflammatory response by disrupting cytokine pathways via inhibition of janus-associated kinases (JAK)
By vgreene, 7 April, 2020 Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19, NCT04336332
By vgreene, 7 April, 2020 Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs Hydroxychlorquine Alone for the Treatment of Confirmed COVID-19, NCT04336332